Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation (Nasdaq: ABSI) is a clinical-stage biopharmaceutical and biotechnology company that frequently issues news related to its generative AI-driven drug discovery platform and internal pipeline of biologic therapeutics. News coverage for Absci often centers on developments in its lead AI-designed antibody programs, platform collaborations, and corporate updates that are relevant to investors and the broader life sciences community.
A major focus of recent Absci news is ABS-201™, an anti-prolactin receptor (PRLR) antibody being developed for androgenetic alopecia and investigated for endometriosis. Press releases have described preclinical human ex vivo data on hair growth, the design and initiation of the Phase 1/2a HEADLINE trial in androgenetic alopecia, and plans for Phase 2 development in endometriosis. Updates also highlight scientific advisory board appointments, key opinion leader seminars, and partnerships aimed at elevating patient perspectives in hair loss research.
Investors following ABSI news can also expect announcements on pipeline progress for programs such as ABS-101, ABS-301, and ABS-501, as well as drug creation partnerships with pharmaceutical, biotech, technology, and academic organizations. Absci has reported collaborations with cloud and hardware providers to support its AI Drug Creation platform, along with participation in healthcare and biotech investor conferences and major industry events.
This news feed aggregates Absci’s press releases and third-party coverage, including items on clinical trial milestones, scientific data presentations, financing and capital markets activity, and corporate governance changes. Readers interested in ABSI can use this page to monitor how Absci’s AI-enabled platform, internal therapeutic programs, and partnerships evolve over time and to track key events that may shape the company’s scientific and business trajectory.
Absci (Nasdaq: ABSI) appointed Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer effective March 3, 2026 to lead clinical development of its AI-designed therapeutics, including flagship ABS-201. Chief Innovation Officer Andreas Busch, Ph.D. will retire March 31, 2026 and transition to co-chair Absci’s Scientific Advisory Board.
Dr. Somaratne joins from Vertex and has prior leadership at BioMarin and Amgen, with experience on Roctavian, Repatha, and Journavx.
Absci (Nasdaq: ABSI) will report business updates and fourth-quarter and full-year 2025 financial and operating results after market close on March 24, 2026.
A webcast and live audio conference call will begin at 4:30 p.m. ET (1:30 p.m. PT), with the live stream and archived replay available via the company’s investor relations site at investors.absci.com.
Absci (Nasdaq: ABSI) will participate in multiple investor conferences in March 2026, including TD Cowen, Leerink Partners, Jefferies Biotech on the Beach, and KeyBanc Healthcare Forum. The company will host fireside chats and 1x1 meetings, with select webcasts available on its investor relations site.
Live and archived webcasts of the TD Cowen, Leerink, and KeyBanc fireside chats will be posted at investors.absci.com, and specific session dates and times are listed for investors.
Absci (Nasdaq: ABSI) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Management is scheduled to present on Wednesday, January 14, 2026 at 3:45 p.m. PT (6:45 p.m. ET). Interested parties can watch a live and archived webcast via the company's investor relations site at investors.absci.com.
The presentation will cover the company's clinical-stage programs and AI-driven therapeutic platform; a webcast will be available for on-demand viewing after the presentation.
Absci (NASDAQ: ABSI) reported new human ex vivo data for ABS-201, an anti‑PRLR antibody, showing it prolongs anagen, stimulates hair matrix keratinocyte proliferation, increases follicular IGF1 and FGF7, and preserves/expands the K15+/CD34+ stem and progenitor pool in organ‑cultured full‑thickness human scalp. Findings suggest ABS-201 may reverse follicle miniaturization by promoting vellus‑to‑terminal reconversion and neutralizing intrafollicular prolactin signaling. The full dataset was presented at Absci’s ABS-201 KOL seminar on Dec 11, 2025 and slides were posted to investor relations.
Absci (Nasdaq: ABSI) announced a partnership with U.S. soccer legend Landon Donovan to raise awareness of androgenetic alopecia (AGA) and the emotional impact of hair loss. Donovan will speak about his personal experience at Absci’s virtual Key Opinion Leader seminar on December 11, 2025, providing patient perspective to guide development of the company’s investigational antibody ABS-201. Absci said it will present additional human ex vivo data supporting the PRLR mechanism of action and discuss the anticipated clinical development path and market opportunity for ABS-201.
The collaboration aims to destigmatize hair loss, highlight unmet treatment needs, and center patient voice in Absci’s AI-driven drug design efforts.
Absci (Nasdaq: ABSI) announced dosing of the first healthy volunteers in the Phase 1/2a HEADLINE trial of ABS-201, an AI-designed anti-prolactin receptor antibody for androgenetic alopecia (AGA).
The randomized, double-blind, placebo-controlled study will enroll up to 227 participants, assess safety, tolerability, PK/PD, immunogenicity and efficacy (TAHC, TAHW, TAHD), and includes SAD (4–6 IV dose groups) and MAD (3–4 SC dose groups) stages. Interim AGA data are expected in H2 2026. Absci plans to start Phase 2 in endometriosis in Q4 2026 with an interim endometriosis readout planned for H2 2027. A KOL seminar is scheduled for Dec 11, 2025.
Absci (Nasdaq: ABSI) reported Q3 2025 results and program updates. Key financials: revenue $0.4M (Q3 2024: $1.7M), net loss $28.7M, and cash, cash equivalents & marketable securities $152.5M, which the company says is sufficient to fund operations into the first half of 2028.
Clinical highlights: interim Phase 1 data for ABS-101 showed extended half-life and no serious adverse events. ABS-201 (anti-PRLR) will start a Phase 1/2a in Dec 2025 with a potential interim efficacy readout in H2 2026 and an expanded Phase 2 in endometriosis expected in Q4 2026 with potential POC in H2 2027. Company to host a KOL seminar on Dec 11, 2025.
Absci (Nasdaq: ABSI) will report business updates and third quarter 2025 financial and operating results after market close on Wednesday, November 12, 2025.
Management will host a webcast and conference call on November 12, 2025 at 4:30 p.m. ET (1:30 p.m. PT) to discuss developments, results, and outlook. Live audio will stream on the company investor relations site at investors.absci.com, and the webcast will be archived for replay after the event.
Absci (Nasdaq: ABSI) announced participation in three investor conferences in November 2025: a Guggenheim Securities fireside chat and 1x1 meetings on Nov 10, 2025 at 10:00 AM ET; UBS Global Healthcare 1x1 meetings on Nov 11, 2025; and a Jefferies Global Healthcare presentation and 1x1 meetings on Nov 18, 2025 at 9:30 AM GMT (4:30 AM ET).
Live and archived webcasts of the Guggenheim and Jefferies sessions will be available on Absci’s investor relations site at investors.absci.com.